Genotypegeleide trombocytenaggregatieremming

Translated title of the contribution: Genotype-guided antithrombotic therapy

Wout W.A. van den Broek*, Jaouad Azzahhafi, Ron H.N. van Schaik, Jurriën M. Ten Berg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Although current literature indicates both a clinical and a cost-effective benefit of routine genotype-guided treatment of patients treated with clopidogrel, this strategy is not recommended in guidelines. In cardiology, but also in neurology and vascular surgery, the current scientific evidence for this is still insufficient. Nevertheless, the role of pharmacogenetics will gain importance in today's medical world, where the demand for personalised medicine is on the rise. The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs. In patients with coronary artery disease and a higher bleeding risk, it is valuable to determine the CYP2C19 genotype prior to treatment with clopidogrel. Pending further studies, we recommend that specialists prescribing clopidogrel should determine the CYP2C19 genotype in patients at high risk of recurrent ischemic events.

Translated title of the contributionGenotype-guided antithrombotic therapy
Original languageDutch
JournalNederlands Tijdschrift voor Geneeskunde
Volume166
Publication statusPublished - 24 Jan 2022

Fingerprint

Dive into the research topics of 'Genotype-guided antithrombotic therapy'. Together they form a unique fingerprint.

Cite this